Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP
NRX Pharmaceuticals (NRXP) Stock Price & Analysis
293 Followers
NRXP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.90 - $7.33
Previous Close$2.33
Volume14.72K
Average Volume (3M)344.99K
Market Cap
$24.93M
Enterprise Value$23.61M
Total Cash (Recent Filing)$1.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Aug 12, 2024EPS Estimate
-$0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.18
Shares Outstanding10,700,609
10 Day Avg. Volume80,154
30 Day Avg. Volume344,992
Standard Deviation0.31
R-Squared0.12
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)-1.88
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.82
Forecast
1Y Price Target
$43.00Price Target Upside1745.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
NRX Pharmaceuticals News
PremiumCompany Announcements
NRX Pharmaceuticals Faces Agreement Termination, Eyes Accelerated Approval
PremiumCompany Announcements
NRX Pharmaceuticals Eyes $30M Refinancing and Funding Deal
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company announced final positive clinical trials data in its Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression.
PartnershipThe company announced a major partnership with Alvogen Pharmaceuticals and Lotus Pharmaceuticals for global development and commercialization of NRX-101 in suicidal bipolar depression with the potential for up to $330 million in milestones and double-digit royalties.
ValuationCurrent valuation attractive: maintaining BUY rating, with a 12-month price target representing significant upside from the current share price.
Bears Say
EarningsNet loss was $6.5 million or EPS of $(0.74) compared with estimates of $(0.55) and consensus of $(0.50).
GuidanceNo guidance: Management did not provide forward guidance.
Operating ExpensesOperating expenses were $6.0 million, up from Q4’s $4.4 million on higher G&A costs.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
NRXP FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was $1.90 and its highest was $7.33 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
Currently, no data Available
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is Aug 12, 2024 which is in 21 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on May 14, 2024. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.05.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is -$0.58.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 10,700,609 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -$0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.572%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Among the largest hedge funds holding NRX Pharmaceuticals’s share is Owl Creek Asset Management, L.P.. It holds NRX Pharmaceuticals’s shares valued at N/A.
---
NRX Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.00 (1745.49% Upside)
$43.00 (1745.49% Upside)
Hedge Fund Trend
Decreased
By 5.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-82.61%
Trailing 12-Months
Company Description
NRX Pharmaceuticals
Big Rock Partners Acquisition Corp. is a blank check company, which was formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, reorganization, recapitalization or other similar business combination with one or more businesses or entities. It focuses on identifying a prospective target business in the senior housing and care industry in the United States. The firm's care segments are commonly divided into four categories: Independent Living; Assisted Living; Memory Care and Nursing Care. The company was founded on September 18, 2017 and is headquartered in Delray Beach, FL.
---
NRXP Earnings Call
Q1 2024
0:00 / 0:00
---
NRXP Stock 12 Month Forecast
Average Price Target
$43.00
▲(1745.49% Upside)
Technical Analysis
Best Analysts Covering NRXP
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-48.34%
reiterated a buy rating 6 months ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -48.34% per trade.
---